Shirish Hirani

Senior Vice President-Program Management & Product Planning at ArQule, Inc.

Shirish Hirani

Shirish Hirani

Senior Vice President-Program Management & Product Planning at ArQule, Inc.

Overview
RelSci Relationships

258

Contact Data
Trying to get in touch with Shirish Hirani? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Shirish Hirani likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Vice President & Chief Business Officer at Ipsen Biopharmaceuticals, Inc.

Relationship likelihood: Average

Chief Financial Officer & Treasurer at ArQule, Inc.

Relationship likelihood: Average

President & Chief Operating Officer at ArQule, Inc.

Relationship likelihood: Average

Chief Executive Officer at ArQule, Inc.

Relationship likelihood: Average

Chief Medical Officer at ArQule, Inc.

Relationship likelihood: Average

Senior Director-Business Development at ArQule, Inc.

Relationship likelihood: Average

Clinical Operations Director at ArQule, Inc.

Relationship likelihood: Average

Senior Vice President-Corporate Strategy, Communication & Finance at ArQule, Inc.

Relationship likelihood: Average

Vice President-Investor Relations & Corporate Communications at ArQule, Inc.

Relationship likelihood: Average

Senior Vice President, Investor Relations & Communications at uniQure NV

Relationship likelihood: Average

In The News
Marketline Newswire
May 24, 2018
ArQule Announces Two Key Appointments
Paths to Shirish Hirani
Potential Connections via
Relationship Science
You
Shirish Hirani
Senior Vice President-Program Management & Product Planning at ArQule, Inc.
Education
PhD, Biochemistry
Career History
Senior Vice President-Program Management & Product Planning
2018 - Current

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. The company was founded in 1993 and is headquartered in Burlington, MA.

Vice President, Drug Development
2005 - Prior

ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA.

Vice President-Drug Development
2002 - 2005

Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Shirish Hirani. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Shirish Hirani's profile does not indicate a business or promotional relationship of any kind between RelSci and Shirish Hirani.